Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at financialmarketpress.com, will continue to monitor these healthtech companies to see if the momentum continues. FinancialMarketPress.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent LXEO Stock Price: $11.94
Summary: Lexeo Therapeutics is a clinical-stage genetic medicine company which defined cardiovascular diseases and APOE4-associated Alzheimer's disease are treated. Lexeo Therapeutics is based in New York City.
Geulah Livshits analyst at Chardan Capital reiterates coverage on Lexeo Therapeutics, Inc. (LXEO) stock in the energy sector with a Buy rating and has set LXEO's stock price target at $23.
TipRanks.com reports that Lexeo Therapeutics, Inc. currently has 5 analysts offering 12-month price targets on LXEO and the consensus is a Strong Buy rating with an average stock price target of $20.80. The most recent LXEO stock price we have is $11.94 and we are not making any LXEO forecasts at this time.
In addition, TradingView issued a rating for LXEO over the next month, Barchart.com has a n/a rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on LXEO. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on LXEO, please click here >>
Veeva Systems, VEEV
Recent VEEV Stock Price: $174.76
Summary: Veeva Systems Inc. offers cloud-based software applications and data solutions for the life sciences industry. The company's product portfolio includes Veeva CRM (customer relationship management), Veeva Vault (content and information management), Veeva Network (customer master and product data management) and Veeva data services (Veeva OpenData and Veeva KOL data).
Luke Sergott analyst at Barclays reiterates coverage on Veeva Systems (VEEV) stock in the energy sector with a Buy rating and has set VEEV's stock price target at $220.
TipRanks.com reports that Veeva Systems currently has 3 analysts offering 12-month price targets on VEEV and the consensus is a Moderate Buy rating with an average stock price target of $189.00. The most recent VEEV stock price we have is $174.76 and we are not making any VEEV forecasts at this time.
In addition, TradingView issued a rating for VEEV over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on VEEV. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on VEEV, please click here >>
ACELYRIN, INC., SLRN
Recent SLRN Stock Price: $5.88
Summary: Acelyrin Inc. is a clinical biopharma company. It focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep. Acelyrin Inc. is based in Agoura Hills, California.
Emily Bodnar analyst at H.C. Wainwright reiterates coverage on ACELYRIN, INC. (SLRN) stock in the energy sector with a Buy rating and has set SLRN's stock price target at $30.
TipRanks.com reports that ACELYRIN, INC. currently has 4 analysts offering 12-month price targets on SLRN and the consensus is a Strong Buy rating with an average stock price target of $30.75. The most recent SLRN stock price we have is $5.88 and we are not making any SLRN forecasts at this time.
In addition, TradingView issued a rating for SLRN over the next month, Barchart.com has a n/a rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on SLRN. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SLRN, please click here >>
Roivant Sciences, ROIV
Recent ROIV Stock Price: $9.09
Summary: Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.
Douglas Tsao analyst at H.C. Wainwright reiterates coverage on Roivant Sciences (ROIV) stock in the energy sector with a Buy rating and has set ROIV's stock price target at $18.
TipRanks.com reports that Roivant Sciences currently has 5 analysts offering 12-month price targets on ROIV and the consensus is a Strong Buy rating with an average stock price target of $16.40. The most recent ROIV stock price we have is $9.09 and we are not making any ROIV forecasts at this time.
In addition, TradingView issued a rating for ROIV over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ROIV. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ROIV, please click here >>
The editors at financialmarketpress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinancialMarketPress.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinancialMarketPress.com.
==============================================================================
